Subsequent Event

3 Months Ended

Mar. 31, 2015

Subsequent Event.

Subsequent Event

Note 14 — Subsequent Event

In April 2015, Abbott sold 40.3 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan.  In the second quarter of 2015, Abbott will record a pretax gain of $206 million on $2.29 billion in net proceeds from the sale of these shares.